A patent has been issued by the European Patent Office to Calyxt, Inc. which
gives them permission to create gene-edited plants by the transient delivery
of sequence-specific nucleases, including CRISPR-Cas9.
"Conventionally, gene editing is performed by delivering DNA to cells," says
Dr. Dan Voytas, Calyxt's Chief Science Officer and University of Minnesota
Professor. "The DNA encodes a nuclease, such as CRISPR-Cas9, which makes the
gene edit. The problem with conventional gene editing is that DNA can
integrate randomly into the genome, creating off-target effects. For
example, genes can be disrupted by the incoming DNA that you didn't intend
to disrupt. Calyxt has accomplished a precise method of gene editing that
creates plants with the desired traits."
Calyxt has been using TALENR in developing better food products, but the
company is continuously trying out new gene editing technologies and
approaches to edit plant genes. Calyxt's intellectual property portfolio is
also strengthened by having licensed from Cellectis two patents of a family
claiming the uses of chimeric nucleases, such as TALENR and CRISPR-Cas9, for
gene editing in any type of cells.